[HARMRED] [Chgo LGBT TF on Sub Ab/use] Chicago-based Pre-Exposure Prophylaxis Study Team Responds to Recent iPrEx Study Results - Forum scheduled for December 15
montelevine at gmail.com
Wed Dec 15 23:10:09 CST 2010
There has been a lot of discussion about pre exposure prophylactic for MSM.
I don't think it's a good idea for MSM or people who inject. Most HIV meds
are not too good for the liver. We see more people dying of liver failure
If given the proper tools and information it has been my experience that
someone who injects wants to take care of themselves and their loved ones.
Using a new syringe each and every time adds to the pleasure. Injection
hygiene is dependent on where a person is fixing and the time they have to
The most effective prevention for sexually active men is to wear a condom
which = a decrease in pleasure and intimacy.
In the gay community HIV is often seen as a manageable, chronic illness.
Since the advent of protease inhibitors perceptions have changed
drastically. Yes, it is manageable, but it's a life time of chemo therapy. I
would also call the pre exposure pill popping chemotherapy.
Would this pre exposure have any effect on developing drug resistance?
On Tue, Dec 14, 2010 at 9:35 PM, Dan Bigg <cra at attglobal.net> wrote:
> *What do people think about devoting energy to giving a pre-exposure
> anti-HIV medication to people injecting when it is not even clear that
> people injecting have sufficient sterile syringes? Could it be a better use
> of resources to buy a sufficient supply of sterile syringes so that all
> people injecting and those they see on outreach can have one shot-one
> sterile syringe???? Instead of a medicine which might prevent infection
> infection once exposed?*
> *Thanks for your thoughts!*
> *Peace, Dan*
> *Keith Green
> keith.green at hektoen.org
> Stroger Hospital of Cook County
> Administration Building - Dept. of Psychiatry
> 1900 W. Polk Street, 8th Floor
> Chicago, IL 60612
> (312) 864-8003
> *FOR IMMEDIATE RELEASE: **
> Chicago-based Pre-Exposure Prophylaxis Study Team Responds to Recent iPrEx
> Study Results
> **Chicago, Illinois - November 29, 2010* - The research team of Project
> PrEPare - a Chicago-based pre-exposure prophylaxis (PrEP) trial being
> conducted through the Adolescent Trials Network for HIV/AIDS Interventions
> (ATN) - is encouraged by recent data demonstrating that antiretroviral drugs
> can prevent HIV infection among men who have sex with men and transgendered
> The Pre-exposure Prophylaxis Initiative, or iPrEX, was the first clinical
> trial of its kind. This study showed that the antiretroviral drug Truvada,
> when offered as a component of a comprehensive prevention package that
> includes condoms, counseling, and regular HIV/STI screening, was associated
> with a 44% reduction in HIV infections in participants who took it compared
> to those who took placebo. Additionally, a nearly 73 percent reduction in
> infections was seen in participants who took the study drug more than 90
> percent of the time.
> "Considering the fact that men who have sex with men continue to be
> disproportionately affected by the HIV epidemic here in Chicago, we are
> extremely excited to have data to support a new addition to the 'toolbox' of
> HIV prevention interventions currently available to us," said Sybil Hosek,
> PhD, Principal Investigator of Project PrEPare. "We must remember, however,
> that this is only the first step in determining whether or not PrEP could
> become a part of a comprehensive HIV prevention package in the real world."
> The iPrEx study followed 2,499 healthy, "high-risk" gay men, transgender
> women, and other men who have sex with men from 11 sites located in Peru,
> Ecuador, Brazil, South Africa, Thailand, and the United States. Participants
> were randomly assigned to take either one tablet of Truvada (a combination
> of tenofovir and emtricitabine) or a placebo once a day. Less than 10
> percent of the study sample was from the U.S., however, and even fewer
> represent the ethnic/racial backgrounds of MSM most severely impacted by HIV
> in this country - Black MSM.
> "Since Truvada is already available and is used as a treatment for HIV
> infection, it is imperative that we educate our communities about the
> encouraging results of this study but caution high-risk individuals about
> its limitations," said Margo Bell, MD, Co-Principal Investigator of Project
> PrEPare. "We don't want people, especially our young people, getting the
> idea that it's as simple as taking a pill a day to prevent HIV. It is just
> not that simple."
> Project PrEPare is designed to explore the acceptability and feasibility of
> a PrEP trial among young men who have sex with men in Chicago. The study is
> primarily funded through the* Eunice Kennedy Shriver* National Institute
> of Child Health and Human Development, with additional support from the
> National Institute on Drug Abuse (NIDA) and the National Institute of Mental
> Health (NIMH). Project PrEPare began enrolling at Chicago's CORE Center and
> the Howard Brown Health Center in November 2009 and was nearly 66 percent
> enrolled upon the release of the iPrEx data.
> "Moving forward, it will be critical that we get to some of the unanswered
> questions around the use of PrEP among young MSM in the U.S. through studies
> like Project PrEPare," said Project Director Keith Green, MSW. "We owe it to
> our study participants and the Chicagoland YMSM community at large to
> provide them with as much information as we can about this new prevention
> technology, so that they can make informed decisions about their health and
> A community forum to discuss the iPrEX data and its potential impact on the
> future directon of Project PrEPare will take place in the Michael Leppen
> Theater at the Center on Halsted, 3656 N. Halsted, on Wednesday, December
> 15th 2010 from 6:30-8:30pm. The discussion will be co-facilitated by Jim
> Pickett, Director of Advocacy for the AIDS Foundation of Chicago and Chair
> of the International Rectal Microbicide Advocates
> For more information on Project PrEPare or to learn how to get involved,
> contact Keith Green at 773-864-8003 or visit*
> HARMRED mailing list
> HARMRED at drcnet.org
-------------- next part --------------
An HTML attachment was scrubbed...
More information about the HARMRED